MX2021014997A - Vanadium agents and metformin as active principles for treating conditions related to insulin resistance. - Google Patents
Vanadium agents and metformin as active principles for treating conditions related to insulin resistance.Info
- Publication number
- MX2021014997A MX2021014997A MX2021014997A MX2021014997A MX2021014997A MX 2021014997 A MX2021014997 A MX 2021014997A MX 2021014997 A MX2021014997 A MX 2021014997A MX 2021014997 A MX2021014997 A MX 2021014997A MX 2021014997 A MX2021014997 A MX 2021014997A
- Authority
- MX
- Mexico
- Prior art keywords
- metformin
- insulin resistance
- vanadium
- agents
- conditions related
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003105 metformin Drugs 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 229910052720 vanadium Inorganic materials 0.000 title 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 title 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000001934 delay Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000003914 insulin secretion Effects 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000000580 secretagogue effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention discloses a pharmaceutical composition in the form of a solution with a concentration of 3 x 10-5 M, composed of metformin decavanadate (MetfDeca) as an active principle and a vehicle of a 10% (v/v) solution of DMSO in water. The said vehicle improves the stability of the agent over time. Also, the active ingredient delays progress and treatment in patients with insulin resistance, hyperglycemia, and impaired glucose metabolism, due to its pharmacodynamics of activating the AKT-AMPK pathway with action on glucose reuptake and a secretagogue effect on insulin release.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2021014997A MX2021014997A (en) | 2021-12-06 | 2021-12-06 | Vanadium agents and metformin as active principles for treating conditions related to insulin resistance. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MX2021014997A MX2021014997A (en) | 2021-12-06 | 2021-12-06 | Vanadium agents and metformin as active principles for treating conditions related to insulin resistance. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021014997A true MX2021014997A (en) | 2023-06-07 |
Family
ID=90526847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021014997A MX2021014997A (en) | 2021-12-06 | 2021-12-06 | Vanadium agents and metformin as active principles for treating conditions related to insulin resistance. |
Country Status (1)
| Country | Link |
|---|---|
| MX (1) | MX2021014997A (en) |
-
2021
- 2021-12-06 MX MX2021014997A patent/MX2021014997A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY26425A1 (en) | FORMULATION AND ANTI-DIABETIC METHOD | |
| HRP20150186T1 (en) | Exendin for treating diabetes and reducing body weight | |
| BR0109336A (en) | A medicament for the prevention, amelioration and / or treatment of a diabetic complication, a suitable or usable medicinal drug thereof, a method for preventing, ameliorating and / or treating a diabetic complication, and neuropathy, and uses of a sugar reducing agent. in postprandial blood and at least one agent selected from an antihypertensive agent, a vasodilating agent and an antihyperlipidemic agent | |
| Fiskum et al. | Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress | |
| Agrawal et al. | Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study | |
| CO6361907A2 (en) | FARMACO TRANSDERMIC SUPPLY USING AN OSMOLIT AND A VASOACTIVE AGENT | |
| NZ592283A (en) | Combination of an insulin and the GLP-1 agonist AVE0010 | |
| EA200900940A1 (en) | PHARMACEUTICAL COMPOSITION CONTAINING PYRAZOL-O-GLUCOSIDE DERIVATIVE | |
| HRP20090446T1 (en) | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level | |
| WO2006123248A3 (en) | Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject | |
| AR026356A1 (en) | METHOD TO TREAT DIABETES | |
| HRP20180327T1 (en) | Agent for use in the case of fructose intolerance | |
| WO2006131923A3 (en) | Novel salts of conjugated psychotropic drugs and processes of preparing same | |
| EP3158990B1 (en) | Formulation for release of nitric oxide | |
| MXPA04007183A (en) | Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes. | |
| DE112016005857T5 (en) | A composition for treating motor neuron disorders and use thereof | |
| KR880005933A (en) | Vitamin B6-Containing Pharmaceutical Formulations | |
| MX2021014997A (en) | Vanadium agents and metformin as active principles for treating conditions related to insulin resistance. | |
| JP2008505087A5 (en) | ||
| WO2007076505A3 (en) | Transferrin and transferrin-based compositions for diabetes treatment | |
| BR0308415A (en) | Methods of treating diabetes using pde11a inhibitors | |
| PE20030277A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING 2- [5- (4-FLUOROPHENIL) -3-PYRIDYLMETHYLAMINOMETHYL] -CHROMANE AND L-DOPA | |
| Zhou | Pyruvate may be a novel intervention of diabetes | |
| Woodman et al. | Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride | |
| DK1697401T3 (en) | Tetrapeptide which regulates blood glucose levels in diabetes mellitus |